Latest Biotech News

Tempus is set to expand its precision oncology and minimal residual disease (MRD) capabilities after signing a definitive agreement to acquire Personalis for about $1.5 billion. Under the terms,...

Bristol Myers Squibb and Nvidia said they will expand their AI computing footprint in a move aimed at building what the companies call the most powerful “AI factory” in life sciences. BMS plans...

Samsung Biologics is moving into peptide ingredient manufacturing by planning to acquire Swiss CDMO PolyPeptide for $1.8 billion in cash. The transaction, announced Monday, would give Samsung...

A Johns Hopkins University team reported early clinical evidence for a KRAS-mutant peptide vaccine aimed at preventing progression in people at high risk for pancreatic ductal adenocarcinoma...

Latigo Biotherapeutics outlined plans for an IPO as it prepares late-stage studies for its oral Nav1.8 inhibitor LTG-001 in a bid to compete in non-opioid pain. In IPO-related disclosures, Latigo...

Kolon’s cell-based gene therapy program suffered a late-stage setback after failing to meet co-primary endpoints in a Phase 3 osteoarthritis trial. In an update tied to Kolon TissueGene’s...

Merck’s Lipfendra became the first oral PCSK9 inhibitor to receive FDA approval, expanding the cholesterol-lowering class beyond injectable therapies. The approval positions Lipfendra as a...

Burning Rock Biotech said it will expand its global approach to homologous recombination deficiency (HRD) testing by deepening its agreement with Myriad. Under the expanded collaboration, Burning...

Veraxa Biotech received scientific advice from Germany’s Paul-Ehrlich-Institute (PEI) regarding the biology and nonclinical development plan for its BiTAC-TCE T-cell engager program. The feedback...

Seer’s board committee rejected a takeover proposal from CEO Farokhzad, concluding the offer undervalued the company’s long-term prospects. In its response, the committee—which included...

Bristol Myers Squibb said it will build an AI supercomputer designed to be the most advanced and energy-efficient in biopharma, expanding its work with Nvidia beyond AI models into large-scale...

A legal analysis highlighted how healthcare AI developers face conflicting requirements across patent strategy, FDA enforcement realities, and HIPAA privacy constraints. The piece argues that...

Burning Rock Biotech and Myriad Genetics agreed to expand global access to homologous recombination deficiency testing. Burning Rock will add the prostate Genomic Instability Score (prGIS)...

Kalshi said it will let users bet on whether drug candidates succeed in clinical trials and whether the FDA approves them, framing the effort as a transparency-first mechanism. The prediction...

The FDA approved Merck’s Lipfendra (an oral PCSK9 inhibitor) for lowering LDL cholesterol in adults with high cholesterol, positioning it as the first pill in a class previously dominated by...

Kolon TissueGene’s cell-based gene therapy failed to meet co-primary endpoints in a Phase 3 osteoarthritis trial. The company said it will hold off on determining next steps while a second...

Scribe Therapeutics filed for an IPO aimed at funding its clinical push for lipid-lowering genetic medicines, targeting a potential $96 million raise. The filing outlines planned use of proceeds...

A new analysis argues that implementation science training could improve how clinical trial findings translate into routine healthcare practice. The study, drawing on evidence from CRO workforce...

Researchers at Johns Hopkins reported Phase 1 results for a peptide-based pancreatic cancer vaccine targeting the most common mutant KRAS variants in high-risk individuals. Published in Cancer...

UK biotech venture funding rebounded in the second quarter of 2026, reaching a record high while geopolitical uncertainty continued to weigh on initial public offering sentiment. The report...